Cardiovascular Care
Intersect on FHIR™ connects cardiovascular genomics, remote patient monitoring, and integrated telehealth into a single care pathway — bringing the genetic counselor, the cardiologist, and the patient together across any distance.
The Clinical Opportunity
Inherited cardiovascular conditions are among the most common hereditary diseases — and among the most undertreated. Each is highly actionable when identified. Each disproportionately affects patients who never reach a genetic counselor.
FH causes severely elevated LDL cholesterol from birth, leading to premature coronary artery disease and heart attack — often before age 50. Standard lipid panels alone miss the hereditary component. Cascade testing of first-degree relatives is the most cost-effective cardiovascular intervention available.
HCM is the most common inherited heart muscle disease — and the leading cause of sudden cardiac death in people under 35. Most patients are asymptomatic until a life-threatening arrhythmia occurs. Genetic diagnosis enables proactive monitoring, activity modification, and device therapy consideration before a catastrophic event.
Long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia cause sudden cardiac death in structurally normal hearts — frequently in children and young adults. Many patients are identified only after a family member dies suddenly. Genetic diagnosis changes everything about how these patients are managed.
The Care Model
Intersect on FHIR™ supports the complete cardiovascular genetics care pathway — from initial risk identification through ongoing remote monitoring — without requiring the patient to travel to an academic center for every touchpoint.
Family history, lipid panel results, or clinical presentation triggers genetic testing referral from the primary care provider.
CPOE · ReferralGenetic counselor conducts a telehealth visit. Test is ordered within the platform. Results return as structured FHIR DiagnosticReport resources.
Telehealth · GenomicsCardiologist reviews genetic findings alongside the full longitudinal record — medications, ECGs, imaging, family history — in a single view.
Genomic Panel · CDSPharmacogenomics-informed medication selection. RPM device enrolled. Care plan documented and visible to every provider in the network.
RPM · PharmacogenomicsContinuous vital monitoring with automated alerts. Virtual follow-up visits. Patient receives summaries and medication reminders via mobile app.
RPM · Mobile · AlertsClinical Panels
Inherited conditions affecting heart structure, lipid metabolism, and cardiovascular risk — the most clinically actionable hereditary cardiovascular diseases.
Inherited electrical disorders causing sudden cardiac death in structurally normal hearts — often in young, otherwise healthy individuals.
Pharmacogenomics
Cardiovascular medicine is among the most pharmacogenomically complex specialties. Statins, beta-blockers, antiarrhythmics, and anticoagulants all have significant gene-drug interactions. Intersect surfaces these at the point of prescribing — not after the adverse event.
When a provider orders a QTc-prolonging drug for a patient with a known LQTS variant, Intersect generates a clinical decision support alert before the order is placed — not after the patient experiences a dangerous arrhythmia.
The pharmacogenomics panel result lives in the FHIR record and is visible to every prescriber. A hospitalist covering overnight who orders a new medication sees the same genomic context as the cardiologist who ordered the original genetic test.
For FH patients requiring high-intensity statin therapy, SLCO1B1 status informs myopathy risk stratification — enabling personalized statin selection and dosing before the patient experiences muscle toxicity.
Remote Patient Monitoring
For patients with identified hereditary cardiovascular risk, remote monitoring is not a convenience — it is a clinical necessity. Intersect on FHIR™ closes the gap between the genetic diagnosis and the ongoing surveillance that makes it actionable.
Wearable device data flows into the FHIR patient record as Observation resources — with automated alerts triggered by configurable thresholds tailored to each patient's condition and risk profile.
Out-of-range readings, trending deterioration, and missed readings surface directly on the provider dashboard — prioritized by severity so the care team focuses on the patients who need attention most.
Telehealth visits built into the same platform as RPM and genomics — so the follow-up visit happens in the context of the complete record, not a separate application with incomplete information.
Patients with hereditary cardiovascular conditions need to understand their diagnosis and stay engaged with their care. The Intersect mobile app puts the right information in their hands.
Health Equity
Familial hypercholesterolemia, inherited arrhythmias, and hypertrophic cardiomyopathy affect all populations with equal frequency. But genetic testing, genetic counseling, and specialist cardiology care are concentrated in academic medical centers — far from the rural and underserved communities that bear a disproportionate burden of cardiovascular mortality.
An academic medical center with a cardiovascular genetics program can extend its reach to every community hospital and FQHC in its service area — through a shared Intersect platform where the specialist reviews results and conducts telehealth visits without the patient traveling.
A rural primary care provider who suspects FH in a patient can order a genetic test, refer to a genetic counselor via telehealth, and have the cardiologist's recommendations visible in the same record — all without leaving the Intersect platform.
The American Heart Association has identified hereditary cardiovascular risk in underserved populations as a strategic priority. Intersect on FHIR™ is purpose-built to address this gap — connecting genomics, remote monitoring, and telehealth in a model designed for reach.
We are seeking a cardiovascular genetics program at a large integrated health system to serve as our first clinical validation partner — co-developing the care model and shaping how genomic data flows across the network. If this is your organization, let's talk.
See how Intersect on FHIR™ connects cardiovascular genomics, remote monitoring, and telehealth into a single care pathway.
Request a Demo